Evidence That Speaks the Language of Access
HTA bodies and payers demand increasingly sophisticated evidence to justify reimbursement. At Kintiga, our Health Economics and Outcomes Research (HEOR) and modelling experts build robust, scientifically credible tools to support your value demonstration. We tailor our approach to your product’s unique profile—whether it’s an ultra-orphan disease with limited data, or a high-volume product facing budget scrutiny. Our work integrates seamlessly with your broader access and pricing strategies.
Our services include:
- Cost-effectiveness and budget impact models (CEAs, BIMs)
- Real-world evidence generation and synthesis
- Burden of disease and unmet need analyses
- Utility measurement and preference studies
- Custom model adaptations for national HTA submissions
We speak the language of both clinicians, HTA bodies and payers—translating clinical value into economic justification that drives decisions.
Our services
Our experienced team uses the latest economic modelling techniques to develop and adapt models based on your bespoke evidence needs. This can involve a simple decision tree, a partitioned survival model, a Markov health state transition model, and in some cases a patient-level simulation approach (the exact methodology and tool will always be based on an expert assessment of your commercial need). Within HEOR we also offer expertise in Artificial Intelligence and tech-enabled Learning. The Kintiga HEOR team is here to help you develop the most robust and compelling economic arguments to support your HTA submission and strategy.
We support with:
- HTA modelling and Early model review
- Building models for you from scratch or repurposing existing models
- Health economic, cost effectiveness, and budget impact modelling (BIM), from early analysis and model review to full model development.
- Evidence generation gap analysis and mitigation planning
- Stakeholder engagement, payer landscape insights, and payer negotiations
- Custom models and insights for local market
- Treatment pathway and model input validation
- Disease area and payer landscape insights research
- Treatment pathway and model input validation
- KOL engagement advisory boards
- Guidance on pricing strategies
